Hucog HP (Human Chorionic Gonadotropin, Highly Purified) is a pharmaceutical-grade hormone preparation designed for clinical use in reproductive medicine and endocrine disorders. Manufactured under stringent quality controls, this highly purified formulation offers reliable biological activity with minimal impurities, making it a trusted choice among healthcare professionals for triggering ovulation, supporting male fertility, and managing specific hormonal conditions. Its consistent potency and excellent tolerability profile ensure predictable therapeutic outcomes in both assisted reproductive technology (ART) cycles and hormonal replacement protocols.

Features

• Contains highly purified human chorionic gonadotropin (hCG) extracted from human urine
• Standardized potency: 2000 IU, 5000 IU, and 10000 IU vial configurations
• Lyophilized powder form for enhanced stability and reconstitution flexibility
• Includes bacteriostatic water for injection as diluent
• Manufactured in compliance with cGMP (current Good Manufacturing Practices)
• Low impurity profile with minimal luteinizing hormone (LH) cross-contamination
• Pre-measured single-dose vials for accurate administration
• Compatible with subcutaneous or intramuscular injection routes

Benefits

• Precisely triggers final follicular maturation and ovulation in controlled ovarian stimulation cycles
• Supports corpus luteum formation and progesterone production post-ovulation
• Stimulates testosterone production in Leydig cells for treating hypogonadotropic hypogonadism in males
• Facilitates testicular descent in cryptorchidism when administered during appropriate developmental windows
• Enables precise timing for oocyte retrieval in in vitro fertilization (IVF) protocols
• Provides consistent hormonal activity with minimal batch-to-batch variability

Common use

Hucog HP is primarily employed in reproductive endocrinology and infertility treatments. In female patients, it is indicated for triggering final follicular maturation in women undergoing superovulation as part of assisted reproductive technology procedures. It is also used to support the luteal phase in certain fertility treatments. In male patients, Hucog HP is prescribed for the treatment of prepubertal cryptorchidism not due to anatomical obstruction and for stimulating testosterone production in hypogonadotropic hypogonadism. Off-label uses may include weight loss protocols when combined with specific dietary regimens, though this application remains controversial and requires careful medical supervision.

Dosage and direction

Dosage varies significantly based on indication, patient factors, and treatment protocol. For ovulation induction: 5,000-10,000 IU as a single injection when follicular maturation is achieved. For luteal phase support: 1,500-5,000 IU administered every few days. For male hypogonadism: 500-4,000 IU 2-3 times weekly. For cryptorchidism: 500-4,000 IU 2-3 times weekly for several weeks. Reconstitute with provided diluent according to vial strength—typically 1-2 ml bacteriostatic water for 5000 IU vial. Administer via subcutaneous or intramuscular injection using aseptic technique. Rotate injection sites to prevent tissue irritation. Timing of administration is critical for ovarian stimulation protocols—typically administered precisely 34-36 hours before planned oocyte retrieval.

Precautions

Use under strict medical supervision with regular monitoring of ovarian response via ultrasound and estradiol levels to prevent ovarian hyperstimulation syndrome (OHSS). In male patients, monitor testosterone levels, hematocrit, and prostate-specific antigen regularly. Use with caution in patients with history of epilepsy, migraine, asthma, or cardiac or renal impairment. May cause fluid retention; exercise caution in patients susceptible to edema. Not recommended for patients with hormone-dependent malignancies. Pediatric use requires careful consideration of potential premature epiphyseal closure. Store unreconstituted product at controlled room temperature (20-25°C); protect from light.

Contraindications

Absolute contraindications include: known hypersensitivity to hCG or any component of the formulation; prior allergic reaction to hCG preparations; pituitary gland tumors or other neoplasms affected by gonadotropins; unexplained uterine bleeding; ovarian cysts or enlargement not due to polycystic ovarian syndrome; prostate cancer or other androgen-dependent neoplasms; precocious puberty; and thrombophlebitis. Relative contraindications include: history of ovarian hyperstimulation syndrome; polycystic ovarian syndrome; obesity (BMI >35); advanced age (>40 years) in fertility treatments; and pre-existing cardiac or renal disease.

Possible side effect

Common adverse effects include: injection site reactions (pain, redness, swelling); headache; irritability; restlessness; fatigue; and edema. Gynecomastia and breast tenderness may occur in male patients. In female patients: mild to moderate ovarian enlargement with abdominal pain; OHSS (in severe cases); and multiple pregnancies. Less frequently reported: fever; rash; urticaria; hair loss; depression; visual disturbances; and precocious puberty in children. Rare but serious: arterial thromboembolism; ovarian torsion; anaphylaxis; and ectopic pregnancy. Most side effects are dose-dependent and reversible upon discontinuation.

Drug interaction

May interact with gonadotropin-releasing hormone analogs (agonists and antagonists) in controlled ovarian stimulation protocols. Concurrent use with other fertility medications (FSH, LH, clomiphene) requires careful dosage adjustment. Corticosteroids may potentiate fluid retention effects. Androgens and anabolic steroids may alter response in male patients. Drugs affecting hormonal balance (e.g., tamoxifen, aromatase inhibitors) may require dosage modifications. No known clinically significant interactions with hepatic enzyme inducers or inhibitors.

Missed dose

If a dose is missed, administer as soon as remembered unless it is close to the next scheduled dose. Do not double the dose to make up for a missed administration. In ovarian stimulation protocols, contact the treating physician immediately as timing is critical—even a few hours’ delay can significantly impact treatment success. For regular maintenance therapy in male patients, resume the regular dosing schedule. Document missed doses in the patient’s treatment record and assess potential impact on therapeutic outcomes.

Overdose

Overdose may lead to exaggerated pharmacological effects including severe OHSS in women (characterized by rapid weight gain, abdominal pain, nausea, vomiting, oliguria, and respiratory distress) and excessive androgen production in men (acne, hirsutism, aggression, and excessive erythrocytosis). Treatment is symptomatic and supportive: monitor vital signs, maintain fluid and electrolyte balance, and provide appropriate symptomatic relief. In severe OHSS, hospitalization may be required for paracentesis, thromboembolism prophylaxis, and management of complications. Dialysis is not effective for removing hCG. Report suspected overdose to poison control center immediately.

Storage

Store unopened vials at controlled room temperature (20-25°C/68-77°F) in original packaging protected from light. Do not freeze. After reconstitution, store in refrigerator (2-8°C/36-46°F) and use within 30 days—discard any unused portion after this period. Do not use if solution appears discolored or contains particles. Protect from extreme temperatures and humidity. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Hucog HP is a prescription medication that must be used under the supervision of a qualified healthcare professional. Individual response may vary based on patient factors and concomitant conditions. Always follow the specific instructions provided by your treating physician. The manufacturer is not liable for any adverse outcomes resulting from improper use, self-medication, or deviation from prescribed protocols. Report any adverse reactions to your healthcare provider and appropriate regulatory authorities.

Reviews

Clinical studies demonstrate Hucog HP’s efficacy in triggering final oocyte maturation with ovulation rates exceeding 85% in appropriately selected patients. Reproductive endocrinologists report consistent luteinizing hormone-like activity with reliable timing of ovulation. Patients appreciate the predictable response and generally good tolerability profile. Some clinicians note fewer injection site reactions compared to other hCG preparations. In male hypogonadism treatment, studies show satisfactory testosterone response in approximately 90% of patients with appropriate dosing. The high purity formulation receives positive feedback for reduced immunogenicity concerns in extended therapy. Overall professional assessment confirms Hucog HP as an effective, well-tolerated option for indicated hormonal therapies.